Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof

US8198311B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• James Sheppeck · Wilmington, US
• John L. Gilmore · Yardley, US
• T. G. Murali Dhar · Newtown, US
• Hai-Yun Xiao · Montgomery, US
• Jianmin Wang · Lo Wu, CN
• Bingwei Yang · Montgomery, US
• Lidia M. Doweyko · Vero Beach, US

Key dates

• Filing date: Oct 31, 2007
• Grant date: Jun 12, 2012
• Expiry date: Dec 25, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically acceptable salt, or hydrate, thereof, wherein X is (Ia); or X is (Ib); or X is (Ic); (Id) is heterocycle or heteroaryl; E is —N—, —NR1—, —O—, —S—, —SO2— or —CR2—; F is —N—, —NR1a—, —O—, —S—, —SO2— or —CR2a—; G is N, —NR1b—, —O—, —S—, —SO2— or —CR2b—, provided that the E-F-G containing heterocyclic ring formed does not contain a S—S or S—O bond, and at least one of E, F and G is a heteroatom; J, Ja, M, Ma, Q, Rx, Ry, R1, R1a, R1b, R2, R2a, R2b, and R3 to R21, Z, Za, Zb, and Zc are as defined above.